NewAmsterdam Pharma Wins First Approval for Ubeslo in Europe

The European Commission authorized Ubeslo (obicetrapib) and Evlarco, a fixed-dose combination with ezetimibe, for hypercholesterolaemia — the first regulatory approval of obicetrapib anywhere.

September 21, 2026

Key facts

European Commission granted marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe) on September 21, 2026.
Both products are approved for adults with primary hypercholesterolaemia and mixed dyslipidaemia.
The approval is the first regulatory clearance of obicetrapib worldwide, per Investing.com and RTTNews.
Menarini Group holds European rights and will commercialize the products; the announcement was made jointly.
Reports on X cite mid-teens-of-millions EUR milestones and up to €833M in total milestones plus royalties from Menarini; these figures were not confirmed in the corroborating press coverage.
NAMS closed at $22.58 on the event date, up 0.4% from $22.49 the prior close.
No SEC filing covering the approval was cited in the source material.

What happened

NewAmsterdam Pharma Co N.V. (NASDAQ: NAMS), a clinical-stage biotech that develops oral medicines for cardiovascular disease, said the European Commission granted marketing authorization for two cholesterol treatments, according to a joint announcement with its partner Menarini Group carried by PR Newswire, GlobeNewswire and the companies' own newsrooms on September 21, 2026.

The two products are Ubeslo, the brand name for obicetrapib as a stand-alone medicine, and Evlarco, a fixed-dose combination of obicetrapib plus ezetimibe. Both are cleared for adults with primary hypercholesterolaemia and mixed dyslipidaemia, conditions in which LDL cholesterol and other blood fats are too high. Investing.com and RTTNews both reported the approval as the first regulatory clearance of obicetrapib anywhere in the world.

Reports on X from accounts including @USCorpFilings, @AlfaFinderUSA and @specsitsdigest described milestone payments to NewAmsterdam in the mid-teens of millions of euros from Menarini and eligibility for up to €833 million in total milestones plus royalties. Those specific figures appear in the X posts; the corroborating web sources confirm the approval itself. MarketScreener and Investing.com noted the approval.

What obicetrapib is

Obicetrapib belongs to a class of drugs called CETP inhibitors. CETP is a protein that moves cholesterol between lipoproteins in the blood; blocking it raises HDL ("good") cholesterol and lowers LDL ("bad") cholesterol. The class has a long history of failures — several earlier CETP inhibitors were abandoned — which is why a first approval matters for NewAmsterdam specifically.

Ezetimibe is an older, widely used generic cholesterol drug that reduces cholesterol absorbed from the intestine. Evlarco combines it with obicetrapib in one tablet, so patients get two mechanisms in a single daily dose.

NewAmsterdam is not commercializing these drugs in Europe itself. Menarini Group, a privately held Italian pharmaceutical company, holds the European rights and will handle marketing and sales there, which is why the approval announcement is a joint one.

What this means

A marketing authorization from the European Commission is the approval that lets a medicine be sold across all EU member states. In Europe it is granted centrally, through the European Medicines Agency, rather than country by country — so one decision covers the whole bloc at once. That is different from the US, where the Food and Drug Administration is the single gatekeeper; NewAmsterdam has not announced an FDA approval for obicetrapib.

Milestone payments are the standard structure of a licensing deal like this one. Rather than paying for a drug up front, the partner pays in stages as the drug clears specific hurdles — regulatory approval being a major one — and then pays royalties, a percentage of sales, once the product is on the market. The up-to-€833 million figure circulating on X is a total across all remaining stages, not a lump sum received now, and the mid-teens-of-millions-euro payment is the tranche tied to this approval. Those figures come from X reports and were not confirmed in the corroborating press coverage.

For a biotech that has spent years funding trials without product revenue, this is the point where a drug stops being a research candidate and starts being a sellable product. What normally happens next is that the partner begins the country-by-country launch process — pricing and reimbursement negotiations with national health systems — and the company reports milestone revenue in its financial statements. The price data show the stock closed at $22.58 on the event date, up 0.4% from the prior close of $22.49, so the market's same-day reaction was muted. Investing.com reported that Stifel reiterated a Buy rating and $50 price target following the approval; that is a single analyst's view, not a forecast of where the shares will trade.

Sources

Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.